CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
Go back to CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026| (NASDAQ: CRSP) | Delayed: 56.56 -0.77 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.33 | 52 Week High | $18.88 | |||
| Open | $58.00 | 52 Week Low | $13.75 | |||
| Day High | $59.34 | P/E | N/A | |||
| Day Low | $55.63 | EPS | $0.00 | |||
| Volume | 3,382,444 | |||||
